AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29889868
Drug: High salience
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High salience (pudding) ergogenic placebo supplement
Trial: 29889868
Drug: Low salience
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low salience (capsules) ergogenic placebo supplement
Trial: 27151015
Drug: VAD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAD chemotherapy
Trial: 22088938
Drug: BCT (tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCT (tobacco dependence treatment before CT scan)
Trial: 22088938
Drug: ACT (CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT (CT scan before tobacco dependence treatment)
Trial: 19773226
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow cells (BMCs)
Trial: 25837499
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg daily
Trial: 17635377
Drug: Lenalidomide 5
RxNorm normalized name: lenalidomide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 5 mg daily
Trial: 10866879
Drug: Ketorolac (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.5 mg/kg dose-1) IV after surgery and every 6 h for 48 h
Trial: 8149689
Drug: Candoxatril (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril (200 mg) given twice daily for 10 days
Trial: 8149689
Drug: Candoxatril (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril (200 mg)
Trial: 23727759
Drug: Whortleberry fruit
RxNorm normalized name: Myrtle whortleberry fruit
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months)
Trial: 21502969
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dutasteride 0.5 mg plus tamsulosin 0.4 mg)
Trial: 19149835
Drug: l-cystine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-cystine and l-theanine
Trial: 16875911
Drug: Pexelizumab bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab bolus plus infusion (n = 2476)
Trial: 16875911
Drug: Pexelizumab bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab bolus plus infusion or bolus only (n = 3429)
Trial: 3756064
Drug: Aminophylline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 0.2 mg kg‐1 min‐1
Trial: 31473512
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg choline/day for 12 weeks
Trial: 31473512
Drug: 930 mg
RxNorm normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 930 mg choline/day for 12 weeks
Trial: 21918168
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL 1% lidocaine)
Trial: 21918168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL saline)
Trial: 17014595
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg twice daily (BID)
Trial: 10736328
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (0.8 g/d)
Trial: 10736328
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (1.6 g/d)
Trial: 10736328
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (2.4 g/d)
Trial: 3073765
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg aspirin per day
Trial: 3073765
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg aspirin per day
Trial: 11440090
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (BSS), 100 mg/kg/d for 5 days
Trial: 7587909
Drug: Orthotic device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthotic device treatment
Trial: 2312473
Drug: Caffeine (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (650 mg)
Trial: 31243478
Drug: Imrecoxib 100
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Imrecoxib 100 mg
Trial: 23391776
Drug: Intravenous antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antihypertensive treatment targeting systolic BP <150 mm Hg
Trial: 23391776
Drug: Intravenous antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antihypertensive treatment targeting systolic BP <180 mm Hg
Trial: 16500015
Drug: ACLS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACLS intervention with early administration of sodium bicarbonate
Trial: 8840939
Drug: Bicarbonate administration
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate administration
Trial: 9202101
Drug: Caffeine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (240 mg)
Trial: 9202101
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee with supplemental caffeine (2 mg/kg body wt)
Trial: 3285017
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg daily via gastrointestinal tract for 21 days or until discharge)
Trial: 25614603
Drug: Caffeine mouth
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine mouth rinse (CAF) 0.3 g/25 ml
Trial: 25614603
Drug: Maltodextrin mouth
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin mouth rinse (MALT) 1.6 g/25 ml
Trial: 22633472
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin (sim80)
Trial: 22633472
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg simvastatin and 10 mg ezetimibe (sim10eze10)
Trial: 17406757
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori treatment with omeprazole, clarithromycin, and amoxicillin for 7 days
Trial: 8971904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 newborns who did not receive antibiotics)
Trial: 29336914
Drug: Prasugrel 60mg
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 60mg loading dose (G3)
Trial: 29336914
Drug: Prasugrel 30mg
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 30mg loading dose (G2)
Trial: 29336914
Drug: Prasugrel 10mg
RxNorm normalized name: Prasugrel 10mg Oral tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 10mg loading dose (G1)
Trial: 19246029
Drug: Dialectical behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behaviour therapy skills training (DBT‐ST)
Trial: 19246029
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group therapy (SGT)
Trial: 17259081
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg suprofen
Trial: 17259081
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg suprofen
Trial: 15088181
Drug: 200 mg/ml
RxNorm normalized name: urea 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/ml iodine concentration
Trial: 15088181
Drug: 250 mg/ml
RxNorm normalized name: urea 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/ml iodine concentration
Trial: 15088181
Drug: 300 mg/ml
RxNorm normalized name: urea 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/ml iodine concentration
Trial: 15088181
Drug: 350 mg/ml
RxNorm normalized name: urea 350 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg/ml iodine concentration
Trial: 11257152
Drug: Hyaluronan (Hyalgan)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (Hyalgan) - 2 ml of 500-730 000 MW hyaluronan, 10 mg/ml in saline, one injection per week for 5 weeks
Trial: 11257152
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (Depomedrol) - 1 ml of methylprednisolone acetate, 40 mg/ml, one injection per week for 3 weeks
Trial: 11257152
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Hyalgan and Depomedrol)
Trial: 9732167
Drug: Terbinafine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 500 mg
Trial: 3391872
Drug: Erythromycin acistrate
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin acistrate (EA) 400 mg tid for 7-14 days
Trial: 3391872
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base enterocoated pellets in capsules (EB enterocapsules) 500 mg tid for 7-14 days
Trial: 3391872
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base enterocoated tablets (EB enterotablets) 500 mg tid for 7-14 days
Trial: 3391872
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base enterocoated pellets in capsules (EB enterocapsules)
Trial: 3391872
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base enterocoated tablets (EB enterotablets)
Trial: 27049100
Drug: Intranasal T-LysYal
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal T-LysYal
Trial: 24916336
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with adriamycin plus ifosfamide
Trial: 24916336
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with gemcitabine and docetaxel
Trial: 21035211
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration
Trial: 21035211
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration
Trial: 19830486
Drug: Iodixanol (Visipaque,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (Visipaque, GE Healthcare, United Kingdom) administered during endovascular procedure, average 99.3 ml (range 60-180 ml)
Trial: 19830486
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no contrast medium administered)
Trial: 11095476
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide followed by 50 mg captopril after 7 days of EE
Trial: 8810655
Drug: Desmin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 100 mg once daily SC
Trial: 8810655
Drug: Desmin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 100 mg twice a day SC
Trial: 8810655
Drug: Desmin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 200 mg once daily IM
Trial: 8810655
Drug: Desmin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin (all doses)
Trial: 1350796
Drug: lisinopril (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (10‐20 mg once daily)
Trial: 1350796
Drug: hydrochlorothiazide (12.5‐25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (12.5‐25 mg once daily)
Trial: 1350796
Drug: beta-blocker +
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker + ACE inhibitor
Trial: 4083464
Drug: Nimodipine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 1.0 micrograms/kg body weight per minute in addition to 0.1 mg fentanyl/patient
Trial: 4083464
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl anaesthesia (mean: 2.45 mg fentanyl/patient)
Trial: 31221297
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (WP) supplementation (35 g daily)
Trial: 28202846
Drug: MFGM tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFGM tablets (1 g MFGM/d)
Trial: 24670140
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Trial: 24670140
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Trial: 24670140
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1) with 0.4 g.kg‐1.h‐1 whey protein hydrolysate
Trial: 22812907
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration 35-36 h prior to oocyte retrieval (Group A)
Trial: 22812907
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration delayed by 1 day (Group B)
Trial: 22812907
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration delayed by 2 days (Group C)
Trial: 20116841
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ulipristal acetate
Trial: 20116841
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg levonorgestrel
Trial: 12919339
Drug: Eight drugs
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight drugs for primary generalized tonic-clonic seizures
Trial: 1462990
Drug: ALG 15
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALG 15 mg/kg just before transplant surgery, ALG 12 mg/kg the first day after transplant, followed by four doses of 10 mg/kg on alternate days
Trial: 1462990
Drug: OKT3 5
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 5 mg just before transplant, followed by four doses of 5 mg/d
Trial: 4028871
Drug: Lymecycline 300
RxNorm normalized name: lymecycline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline 300 mg
Trial: 26091383
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg
Trial: 28535959
Drug: 1ml/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml/kg of 0.25% caudal‐bupivacaine and 1mg/kg rectal‐diclofenac
Trial: 28535959
Drug: 1ml/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml/kg of 0.25% caudal‐bupivacaine and 30mg/kg rectal paracetamol
Trial: 21659058
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium (6x419 mg Mg chloride/capsule per day for a month)
Trial: 16555167
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract STW3-VI (900 mg)
Trial: 16279863
Drug: Olanzapine combined
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine combined with fluoxetine
Trial: 16279863
Drug: Risperidone added
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone added to ongoing therapy
Trial: 10996349
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (1 or 2 tablets per day)
Trial: 10996349
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (1 tablet per day)
Trial: 6152029
Drug: Propiomazine 25
RxNorm normalized name: PROPIOMAZINE
DrugBank: Propiomazine (DB00777)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propiomazine 25 mg
Trial: 1337553
Drug: Azithromycin, 10
RxNorm normalized name: Azithromycin, 100 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 10 mg/Kg/day per os once daily for 3 days or 10 mg/Kg/day on day 1 and 5 mg/Kg/day on days 2-5 (77 patients)
Trial: 1337553
Drug: Erythromycin, 50
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 50 mg/Kg/day thrice daily for at least 7 days (74 patients)
Trial: 30566442
Drug: Enquiry about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enquiry about clients' medication response
Trial: 25230681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low saturated fat intake and high cardiorespiratory fitness
Trial: 7596933
Drug: Fluconazole, 400
RxNorm normalized name: Fluconazole, 400 mg/200 mL-5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 400 mg/day
Trial: 484644
Drug: Anaprox (1,100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaprox (1,100 mg)
Trial: 30068215
Drug: Walnut inclusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut inclusion (56 g of walnuts daily for 6 months)
Trial: 28441618
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use (alcohol and illicit drugs)
Trial: 22540330
Drug: STICA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STICA treatment (manualized short-term treatment of IA/CA)
Trial: 343006
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg prazosin
Trial: 343006
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prazosin
Trial: 19565569
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IGla)
Trial: 31301668
Drug: IVT ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IVT ranibizumab (3 injections 0.5 mg)
Trial: 31301668
Drug: IVT ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IVT ranibizumab (1 injection 0.5 mg) + LP
Trial: 31301668
Drug: Dexamethasone IVT
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone IVT implant (0.7 mg)
Trial: 31301668
Drug: Dexamethasone IVT
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone IVT implant (0.7 mg) + LP
Trial: 23568174
Drug: Formulation M
RxNorm normalized name: Complete Formulation Minis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation M + OPV placebo
Trial: 23568174
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations of DTaP-sIPV
Trial: 21751165
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate pre-treatment (1.0 g/day for 6 days before and 3 days after radioiodine therapy)
Trial: 21751165
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate pre-treatment
Trial: 21751165
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy with lithium carbonate pre-treatment